Twice-Yearly Schizophrenia Tx OK'd; Austedo Effective Long-Term; $$ for Sobriety

(MedPage Today) -- The FDA approved the injectable, long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera), a twice-yearly treatment for schizophrenia in adults who have been adequately treated with the 1- or 3-month versions...